By Chrissy Buteas, President and CEO, HealthCare Institute of New Jersey (HINJ – www.hinj.org) and Dan Leonard, Executive Director, We Work For Health (WWFH – www.weworkforhealth.org)
Published on April 29, 2006 by TAPInto’s New Jersey affiliates in Bayonne, Hamilton, Hoboken, Jersey City, Nutley, Paterson, and Wayne
April 29, 2026 ― Making medicines more affordable is a goal we all share. Patients, employers, innovators, and policymakers recognize that high costs can stand between patients and the care they need. But not every policy that promises lower prices delivers better outcomes. If policymakers were to codify a “most favored nation” (MFN) drug pricing policy – which would tie U.S. prices to those set by foreign governments – it would come at an extraordinary cost to patients, America’s scientific leadership, and New Jersey jobs. Read the full op ed here.